Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 2/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | YAP1 | P46937 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | STS | P08842 | 2/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047995 | 0.78 | CTSS (0.46) | KMT2AGPR119 | |
| SCHEMBL7137297 | 0.78 | ALDH1A1 (0.42) | KMT2AMEN1YAP1GPR119STS | |
| SCHEMBL7137802 | 0.76 | CTSK (0.44) | — | |
| SCHEMBL7136828 | 0.75 | KMT2A (0.57) | KMT2AMEN1YAP1GPR119STS | |
| SCHEMBL7133720 | 0.75 | MEN1 (0.43) | KMT2AMEN1YAP1GPR119STS | |
| SCHEMBL7134284 | 0.71 | PTPRB (0.40) | PTPRBPTPN11KMT2AYAP1GPR119 | |
| SCHEMBL7137524 | 0.70 | YAP1 (0.44) | PTPRBPTPN11KMT2AYAP1GPR119 | |
| SCHEMBL15724529 | 0.69 | CTSK (0.54) | — | |
| SCHEMBL22929136 | 0.69 | YAP1 (0.65) | YAP1GPR119 | |
| SCHEMBL13282013 | 0.67 | MAOB (0.53) | GPR119PTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | PTPRB 2107/4885PTPN11 1685/4885KMT2A 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.